Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRA | P10827 | 14/20 | 0.59 |
| ▸ | THRB | P10828 | 14/20 | 0.59 |
| ▸ | NR3C1 | P04150 | 4/20 | 0.53 |
| ▸ | ESR1 | P03372 | 1/20 | 0.53 |
| ▸ | PGR | P06401 | 1/20 | 0.53 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.53 |
| ▸ | AR | P10275 | 1/20 | 0.53 |
| ▸ | FFAR4 | Q5NUL3 | 3/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5105873 | 0.91 | THRA (0.58) | THRATHRBNR3C1ESR1PGR | |
| SCHEMBL5116725 | 0.89 | THRA (0.60) | THRATHRBNR3C1ESR1PGR | |
| SCHEMBL5112565 | 0.89 | THRA (0.63) | THRATHRBNR3C1ESR1PGR | |
| SCHEMBL4931352 | 0.88 | THRA (0.64) | THRATHRBNR3C1ESR1PGR | |
| SCHEMBL5722595 | 0.87 | THRA (0.45) | THRATHRBNR3C1ESR1PGR | |
| SCHEMBL5117039 | 0.86 | THRA (0.54) | THRATHRBNR3C1ESR1PGR | |
| SCHEMBL4932301 | 0.86 | THRA (0.59) | THRATHRBNR3C1ESR1PGR | |
| SCHEMBL5118891 | 0.86 | THRA (0.51) | THRATHRBNR3C1ESR1PGR | |
| SCHEMBL4559404 | 0.86 | THRA (0.64) | THRATHRBNR3C1ESR1PGR | |
| SCHEMBL5104139 | 0.86 | THRA (0.61) | THRATHRBNR3C1ESR1PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080004251-A1 | Novel Pharmaceutical Compositions Comprising Agonists of the Thyroid Receptor | KARO BIO AB (SE) | 2008-01-03 | — | — | US | disclosed |
| EP-1732532-A1 | NOVEL PHARMACEUTICAL COMPOSITIONS COMPRISING AGONISTS OF THE THYROID RECEPTOR | KARO BIO AB (SE) | 2006-12-20 | — | — | EP | disclosed |
| WO-2005092316-A1 | NOVEL PHARMACEUTICAL COMPOSITIONS COMPRISING AGONISTS OF THE THYROID RECEPTOR | KARO BIO AB (SE) | 2005-10-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080004251-A1 | Novel Pharmaceutical Compositions Comprising Agonists of the Thyroid Receptor | TSHR, TRHR, THRA | THRA 3/4885THRB 4/4885NR3C1 107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.